An additional layer of protection, alongside the gluten-free diet.
What is celiac disease?
Celiac disease is a chronic, immune-mediated condition. In people who are genetically susceptible, eating gluten, a protein found in wheat, barley, and rye, triggers an immune response that damages the lining of the small intestine.
- Common: affects about 1% of people in the United States, and many remain undiagnosed
- Varied symptoms: may include diarrhea, abdominal pain, bloating, fatigue, and headache
- No approved medicine: the only management is a strict, lifelong gluten-free diet
Even with careful adherence, accidental gluten exposure is common, and some people continue to experience symptoms or intestinal damage, highlighting the need for additional treatment options.
More than avoiding gluten
Living with celiac disease goes beyond avoiding gluten. Eating out, traveling, dating, and sharing meals with family and friends can all present challenges, and for children, the burden extends to caregivers, school, and social settings.
Because gluten is so common in the food supply, accidental exposure can happen even with careful adherence to the diet. Approximately 70% of people with celiac disease report recurrent signs and symptoms despite a gluten-free diet, and damage to the intestinal lining can occur even without noticeable symptoms. This highlights the need for additional treatment options that can work alongside the gluten-free diet.
of people with celiac disease surveyed by Beyond Celiac (2025) reported being concerned or embarrassed about eating in front of others.
Frequently asked questions
How does larazotide work?
Larazotide acetate is an investigational medicine designed to help protect the intestinal barrier. In people with celiac disease, gluten exposure can disrupt the tight junctions between cells lining the small intestine, allowing gluten fragments to cross the intestinal barrier and contribute to an immune response. Larazotide is designed to regulate these tight junctions and reduce gluten-induced intestinal permeability. It works locally in the gut, is not designed to suppress the immune system, and remains investigational.
What is known about the safety of larazotide?
In clinical studies to date, larazotide has been generally well tolerated, with side effects similar to those reported with placebo, and no significant safety issues have been reported. Approximately 800 patients have received larazotide acetate in clinical studies. Larazotide is investigational: its safety and effectiveness, including for long-term use, have not been established and continue to be studied.
When and where can I join a clinical trial?
Interlude’s Phase 3 trial, CeD-LA-3002, will be conducted at clinical sites in the United States, with the first participant anticipated in the first quarter of 2027. Information about eligibility and participating sites will be available through ClinicalTrials.gov and the study sites, which can provide screening details. To register your interest in the study, contact info@interludebio.com.
Does larazotide replace a gluten-free diet?
No. Larazotide acetate is being developed as a potential daily addition to the gluten-free diet, not a replacement for it, and it is not intended to permit gluten consumption. People with celiac disease should continue to follow a strict gluten-free diet.
Is larazotide FDA-approved?
No. Larazotide acetate is investigational and has not been approved by the FDA or any other regulatory authority. It has received FDA Fast Track designation for celiac disease, which is intended to facilitate the development of drugs for serious conditions with an unmet medical need. Fast Track designation does not mean that larazotide has been shown to be safe or effective.